Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy
- 111 Downloads
Growing literature supports good survival expectancies in bladder cancer (BCa) patients affected by clinical node metastases (cN+) treated with multimodal therapy. We evaluated the role of adjuvant chemotherapy in cN+BCa patients treated with radical cystectomy (RC) and pelvic lymph node dissection (PLND) without neoadjuvant chemotherapy (NAC).
We evaluated a total of 192 patients with BCa and cN+. All patients were treated with RC and PLND without NAC between 2001 and 2013. Kaplan–Meier analyses and Cox regression analyses were used to assess the impact of adjuvant chemotherapy (ACT) on recurrence, cancer-specific mortality (CSM) and overall mortality (OM) after surgery.
Overall, 99 patients (51.6%) were found without node metastases at RC, while 18 (9.4%), 58 (30.2%) and 17 (8.9%) patients were found pN1, pN2 and pN3, respectively. With a median follow-up of 48 months, in cN+ patients we recorded 5-year recurrence, CSM and OM of 55, 53 and 51%, respectively. Overall, 36 (18.8%) patients were treated with adjuvant chemotherapy. At univariable analyses, ACT was associated with improved overall survival [Hazard ratio (HR): 0.42, confidence interval (CI) 0.20–0.86, p = 0.02) in pN+ subgroup only. These results were confirmed at multivariable analyses, where ACT was associated with improved CSS (HR: 0.45, CI 0.21–0.89, p = 0.03) and OS (HR: 0.37, CI 0.17–0.81, p = 0.01).
We report good survival outcomes in cN+ patients treated with RC. The use of ACT after surgery increases survival expectancies, especially in those patients with pathological node disease. Our data need to be further evaluated in prospective setting.
KeywordsClinical metastases Radical cystectomy Bladder cancer Clinical node positive Metastases Survival
MM Project development, Manuscript writing, Data analysis. AM Project development. JC Project development, Data Collection. SFS Manuscript writing, Data analysis. PDO Project development, Data Collection. EZ Project development, Data Collection. AS Manuscript writing, Data analysis. FM Manuscript writing, Data analysis. AB Project development. RC Project development. AG Project development, Manuscript writing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All person gave their informed consent to use their data for this retrospective study.
- 2.Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE et al (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176:2414–2422. https://doi.org/10.1016/j.juro.2006.08.004 (discussion 2422) CrossRefPubMedGoogle Scholar
- 4.Moschini M, Karnes RJ, Sharma V, Gandaglia G, Fossati N, Dell’Oglio P et al (2016) Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience. Eur J Surg Oncol 42(5):735–743. https://doi.org/10.1016/j.ejso.2016.02.011 CrossRefPubMedGoogle Scholar
- 7.Moschini M, Morlacco A, Briganti A, Hu B, Colombo R, Montorsi F et al (2016) Clinical lymphadenopathy in urothelial cancer: a transatlantic collaboration on performance of cross-sectional imaging and oncologic outcomes in patients treated with radical cystectomy without neoadjuvant chemotherapy. Eur Urol Focus. https://doi.org/10.1016/j.euf.2016.11.005 Google Scholar
- 8.Galsky MD, Stensland K, Sfakianos JP, Mehrazin R, Diefenbach M, Mohamed N et al (2016) Comparative effectiveness of treatment strategies for bladder cancer with clinical evidence of regional lymph node involvement. J Clin Oncol 34:2627–2635. https://doi.org/10.1200/JCO.2016.67.5033 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Ho PL, Willis DL, Patil J, Xiao L, Williams SB, Melquist JJ et al (2016) Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: the M.D. Anderson Cancer Center Experience. Urol Oncol 34(59):1–8. https://doi.org/10.1016/j.urolonc.2015.08.012 Google Scholar
- 10.Zargar-Shoshtari K, Zargar H, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S et al (2015) A multi-institutional analysis of outcomes in patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy. J Urol. https://doi.org/10.1016/j.juro.2015.07.085 PubMedCentralGoogle Scholar
- 12.International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder et al (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177. https://doi.org/10.1200/JCO.2010.32.3139 CrossRefGoogle Scholar
- 14.Greene FL, Page DL, Fleming IDE (2002) Urinary bladder. In: AJCC Cancer Staging Manual. 6 (Edn) Springer, New YorkGoogle Scholar
- 15.Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U et al (2010) International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105:1402–1412. https://doi.org/10.1111/j.1464-410X.2010.09217.x CrossRefPubMedGoogle Scholar
- 16.Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y et al (2010) Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol 183:2165–2170. https://doi.org/10.1016/j.juro.2010.02.021 CrossRefPubMedGoogle Scholar
- 18.Moschini M, Jeffrey Karnes R, Gandaglia G, Luzzago S, Dell’Oglio P, Rossi MS et al (2016) Preoperative favorable characteristics in bladder cancer patients cannot substitute the necessity of extended lymphadenectomy during radical cystectomy: a sensitivity curve analysis. Urology 88:97–103. https://doi.org/10.1016/j.urology.2015.12.005 CrossRefPubMedGoogle Scholar